ClinicalTrials.gov
ClinicalTrials.gov Menu

Hybrid Closed-Loop Hotel Studies With Medtronic PID Controller

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02280863
Recruitment Status : Completed
First Posted : November 3, 2014
Results First Posted : July 3, 2018
Last Update Posted : July 3, 2018
Sponsor:
Information provided by (Responsible Party):
Bruce A. Buckingham, Stanford University

Brief Summary:
The primary objective of this study is to evaluate the safety and efficacy of the Medtronic hybrid closed-loop (HCL) system utilizing the proportional-integral-derivative algorithm with insulin feedback (PID-IFB) optimized to function in a hybrid mode with closed-loop control operating during the day and night.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Device: Medtronic Hybrid Closed-loop System - Android Platform Device: Medtronic Hybrid Closed-loop Integrated System Not Applicable

Detailed Description:

Study participants will be asked to use the CGM and the study insulin pump provided for approximately 4 to 5 days prior to initiation of the HCL PID-IFB system in a hotel setting for another 4 to 5 days. All participants with diabetes and the parent/ guardian of participants < 18 years of age will be asked to stay overnight in a hotel while the HCL PID-IFB system is on and to remain close to Stanford University during the day. For participants > 18 years of age, designated remote monitors will be asked to receive alerts for low/ high glucose levels.

Enrolled participants will be asked to complete evaluations to describe their user experience/ evaluation of the system.Each participant had a companion (parent/ legal guardian of participants < 18 years of age, or the designate remote monitor for participants > 18 years of age) who will consent to monitor the participant and complete an evaluation, but will not be considered enrolled in the study.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Hybrid Closed-Loop Studies With Medtronic PID Controller- Hotel HCL Study
Study Start Date : July 2014
Actual Primary Completion Date : May 2015
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Adult Cohort
Medtronic Hybrid Closed-Loop System will be used by adults for five days in open-loop (sensor augmented pump) and five days in closed-loop. The first 8 Adults use the Android Platform.
Device: Medtronic Hybrid Closed-loop System - Android Platform
A continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm using an Android controller.

Device: Medtronic Hybrid Closed-loop Integrated System
A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm

Experimental: Adolescent Cohort
Medtronic Hybrid Closed-Loop System will be used by adolescents for four days in open-loop (sensor augmented pump) and four days in closed-loop.
Device: Medtronic Hybrid Closed-loop Integrated System
A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm




Primary Outcome Measures :
  1. Count of Participants With no More Than One Meter Glucose Value <50 mg/dL and no Values <40 mg/dL, no More Than Two Episodes With Meter Glucose Values Remaining >300 mg/dL for More Than 1 Hour, and no Ketonemia, Seizures, or Loss of Consciousness [ Time Frame: Up to 10 days ]

    Our definition of a subject successfully participating in a cohort is:

    1. No more than one meter glucose value <50 mg/dL and no values <40 mg/dL
    2. No more than two episodes with meter glucose values remaining >300 mg/dL for more than 1 hour that are unrelated to an infusion set failure
    3. No ketonemia >1.0 mmol/L, while the system is functional unless related to an intercurrent illness or infusion set failure
    4. No seizures or loss of consciousness while system is on and functional


Secondary Outcome Measures :
  1. Mean Glucose Values [ Time Frame: Up to 10 days ]
    Mean glucose values are reported as assessed by continuous glucose monitoring (CGM; subcutaneous sensor, day and night values).

  2. Mean Glucose Values, Fingerstick Glucose Meter Value, Adult Cohorts [ Time Frame: Up to 10 days ]
    Mean glucose values are reported as assessed by fingerstick glucose meter value.

  3. Median Glucose Values, Fingerstick Glucose Meter Value, Adolescent Cohort [ Time Frame: Up to 10 days ]
    Median an glucose values are reported as assessed by fingerstick glucose meter value.

  4. Percentage of Time Within Glucose Range of 70-180 mg/dL [ Time Frame: Up to 10 days ]
  5. Percentage of Fingerstick Meter Glucose Value Tests <70 mg/dL [ Time Frame: Up to 10 days ]
  6. Percentage of Time With Sensor Glucose Values <70 mg/DL, Adult Cohorts [ Time Frame: Up to 10 days ]
  7. Percentage of Time With Sensor Glucose Values <70 mg/DL, Adolescent Cohort [ Time Frame: Up to 10 days ]
  8. Percentage of Fingerstick Meter Glucose Value Tests >300 mg/dL, Adult Cohort - Medtronic Android Interface [ Time Frame: Up to 10 days ]
  9. Percentage of Fingerstick Meter Glucose Value Tests >300 mg/dL, Adult Cohort - Integrated System Interface and Adolescent Cohort [ Time Frame: Up to 10 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   14 Years to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Clinical diagnosis of type 1 diabetes (The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.)
  • Daily insulin therapy for at least one year
  • Age between 14.0 to 40.0 years of age. The first 9 subjects (between all 3 centers) will be over 18 years old.
  • Subject has performed an average of at least 3 meter glucose readings per day in the preceding 2 weeks
  • Subject has used a downloadable insulin pump for at least 3 months
  • Subject comprehends written English
  • Female patients who are sexually active must be on acceptable method of contraception e.g. oral contraceptive pill, diaphragm, IUD
  • Female patients must have a negative urine pregnancy test
  • Informed Consent Form signed by the subject and/or parent and assent signed by the subject if < age 18
  • Parent/guardian (for subjects < 18 years) and subject understand the study protocol and agree to comply with it. Both parents must sign if possible.
  • Total daily insulin requirement greater than 0.4 units/kg/day over the preceding two weeks.
  • No expectation that subject will be moving out of the area of the clinical center during the study.
  • Adults will need to be working within 20 minutes of our research staff during the day.
  • A person willing to fulfill the role of a remote monitor (such as parent, spouse or significant other).

Exclusion Criteria:

  • Subject has a medical disorder that in the judgment of the investigator will affect the wearing of the devices or the completion of any aspect of the protocol
  • Diabetic ketoacidosis in the past month
  • History of seizure or loss of consciousness in the last 6 months
  • Subject has a respiratory condition such as asthma, treated with systemic or inhaled corticosteroids in the previous 6 months or cystic fibrosis
  • Subject has a history of any cardiac or vascular disorder such as myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, arrhythmia or thromboembolic disease
  • Subject has a history of liver or kidney disease (other than microalbuminuria)
  • Systolic blood pressure > 140 mmHg on screening visit
  • Diastolic blood pressure > 90 mmHg on screening visit
  • Subject has active Graves' disease
  • Subjects with inadequately treated thyroid disease or celiac disease
  • Subject has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol
  • Either the subject or the subject's primary caregiver has received inpatient psychiatric treatment in the past 6 months
  • Subject has a history of diagnosed medical eating disorder
  • Subject has a history of known illicit drug abuse
  • Subject has a history of known prescription drug abuse
  • Subject has a history of current alcohol abuse
  • Subject has a history of visual impairment which would not allow subject to participate
  • Subject has an active skin condition that would affect sensor placement
  • Subject has adhesive allergies
  • Subjects requiring an intermediate or long-acting insulin (such as NPH, detemir or glargine)
  • Subjects requiring other anti-diabetic medications other than insulin (oral or injectable)
  • Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
  • Subject is currently on beta blocker medication
  • Subject is currently participating in another investigational study (drug or device)
  • Subject is deemed by the investigator to be unwilling or unable to follow the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02280863


Locations
United States, California
Stanford University Medical Center
Stanford, California, United States, 94305
United States, Colorado
UC Denver- Barbara Davis Center for Childhood Diabetes
Aurora, Colorado, United States, 80045
United States, Connecticut
Yale University- Department of Pediatric Endocrinology
New Haven, Connecticut, United States, 06520
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Bruce A Buckingham, MD Stanford University

Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Bruce A. Buckingham, Principle Investigator, Stanford University
ClinicalTrials.gov Identifier: NCT02280863     History of Changes
Other Study ID Numbers: IDE: G140086
1-SRA-2014-238- ( Other Grant/Funding Number: JDRF Grant Key: 1-SRA-2014-238-M-R )
IRB 29973 ( Other Identifier: Stanford University )
First Posted: November 3, 2014    Key Record Dates
Results First Posted: July 3, 2018
Last Update Posted: July 3, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: There were three sites involved with the study; de-identified information was shared with the Denver and Yale sites.

Additional relevant MeSH terms:
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Methyltestosterone
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs